Please assess the completion status of the following clinical trial:

Trial Title: International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age greater than or equal to 18 years.~2. Ability to provide informed consent or assent.~3. Prior successful participation in a tolvaptan hyponatremia trial termination with evidence of continued need or desire for therapy.~Exclusion Criteria:~* A current medical condition where long-term treatment with an aquaretic agent may present an undue risk to the patient.~* Hyponatremia which is acute, reversible, artifactual or due to conditions not associated with vasopressin excess or likely to respond to aquaretic therapy.~* Hyponatremia due to reversible medical condition or therapy~* Conditions associated with an independent imminent risk of morbidity and mortality~* Conditions which confound the assessment of endpoints.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).